Sorry, you need to enable JavaScript to visit this website.

Mechanism of Action | RYBREVANT® (amivantamab-vmjw) HCP

3-Pronged MOA

divider-mb

RYBREVANT® is a bispecific antibody that binds to the extracellular domains of EGFR and MET, and acts with a 3-pronged approach1:

  • Block ligand binding1
RYBREVANT® blocks EGFR and MET activity
  • Receptor degradation1
RYBREVANT® degrades EGFR and MET receptors
  • Antibody-dependent cellular cytotoxicity and trogocytosis​1
RYBREVANT® activates immune cell responses to kill tumor cells

The presence of EGFR and MET on the surface of tumor cells allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.1

EGFR, epidermal growth factor receptor; MET, Mesenchymal-Epithelial Transition.

Explore

cnt-divider

insertionlogo

EGFR Exon 20 Insertion Mutations

Learn about EGFR exon 20
insertion mutations.

Learn more

efficacylogo

Efficacy

Explore the results from the
CHRYSALIS trial.

Learn more

safetylogo

Safety

Review the safety profile
of RYBREVANT®.

Learn more

register

Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.

Reference

1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.